APGE - CIK 0001974640
The table below shows Apogee Therapeutics, Inc.'s cash flow statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating cash flow | -$227.45M | -$171.17M | -$74.76M | -$16.43M |
| Capital expenditure | $5.15M | $1.15M | $167.00K | - |
| Investing cash flow | -$179.57M | -$300.46M | -$273.91M | - |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $396.49M | $495.11M |
Apogee Therapeutics, Inc. reported operating cash flow of -$227.45M for fiscal year 2025. That is down 32.9% from -$171.17M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $315.39M |
| $168.32M |